Full-Time

Product Expert Treasury Management Technology

Posted on 8/20/2026

Deadline 8/31/26
Haleon

Haleon

10,001+ employees

Global consumer health care products company

No salary listed

Bengaluru, Karnataka, India

In Person

Bachelor's, Master's

Category
Product (1)
Required Skills
Bloomberg
Agile
Forecasting
Product Management
SQL
Risk Management
iOS/Swift
Data Analysis

Get referred to Haleon

See people who can refer or advise you

Requirements
  • A minimum of 10 years of experience with FIS Quantum, including configuration, integration, and administration.
  • Experience with FIS Quantum modules including Cash Management & Forecasting, Foreign Exchange & Hedge Accounting, and Payments & Bank Connectivity, along with the business processes those modules support.
  • Hands-on experience supporting day-to-day treasury operations, including tracking payments and bank statements, using FIS Trax and SWIFT, and liaising with banking partners.
  • Hands-on experience integrating FIS Quantum with third-party market data providers, including Bloomberg and LSEG Workspace.
  • Proven experience integrating FIS Quantum with SAP ERP and other enterprise systems to support treasury operations and data workflows.
  • Experience working with compliance and control frameworks and preparing for and supporting internal and external application audits.
  • A proven track record in SaaS product management, solution design, and delivery, ideally in a global or multi-country environment.
  • Familiarity with integrations to internal and external finance and access management systems, such as SAP ECC/S4HANA, SailPoint, and CyberArk.
  • Experience working with and managing third-party service providers and software vendors.
  • Strong analytical, problem-solving, and communication skills.
Responsibilities
  • Develop and maintain a product roadmap that reflects business priorities, regulatory requirements, and user needs.
  • Identify opportunities for new features, integrations, and process improvements that drive business value.
  • Lead the gathering, analysis, and prioritization of business and technical requirements from diverse stakeholders, ensuring clarity and traceability throughout the product lifecycle.
  • Maintain comprehensive documentation covering system architecture, security, compliance, and operational processes, ensuring accessibility and audit readiness.
  • Oversee end-to-end delivery of FIS Quantum solutions, including integration, deployment, upgrades, and enhancements.
  • Manage project scope, timelines, and resources to deliver against agreed milestones and budgets.
  • Manage system changes according to the Haleon Change Management procedure, ensuring auditor traceability for all system changes.
  • Coordinate across Technology, Treasury, Finance, and external vendors to ensure seamless execution and issue resolution.
  • Engage internal stakeholders to understand business needs, communicate product changes, and gather feedback for continuous improvement.
  • Manage relationships with external vendors and service providers, including performance monitoring and escalation of service issues.
  • Facilitate regular stakeholder meetings to ensure alignment and transparency.
  • Ensure compliance with regulatory requirements such as SOX and GDPR, internal policies, and industry standards.
  • Embed risk management practices into product operations, including regular risk assessments, mitigation planning, and audit preparation and support.
  • Ensure controls operate effectively and remediate control or audit findings within agreed timelines.
  • Maintain and test business continuity and disaster recovery plans for critical applications.
  • Act as a subject matter expert for FIS Quantum, providing guidance and support to end users, stakeholders, and Technology colleagues.
  • Lead user adoption initiatives, including training, communication, and support for automation, new features, and process changes.
Desired Qualifications
  • FIS certification and/or SAP Finance-related certifications.
  • Experience designing and/or operating SOX controls.
  • Experience with data analytics, SQL, and reporting tools.
  • Experience supporting change management and user adoption initiatives.
  • Exposure to Agile and Waterfall delivery methodologies.
  • Experience working with diverse, cross-functional teams across multiple geographies.

Haleon is a global consumer health company that develops and sells everyday health products under brands such as Sensodyne, Advil, and Centrum. Its products address oral care, pain relief, immunity, and general well-being, working through science-backed formulations people use daily. Haleon differentiates itself by being a focused, standalone consumer health business formed from GSK’s spin-off and built from leading brands through major acquisitions, operating at scale with a portfolio of category leaders and competing with peers like Kenvue and Procter & Gamble. Its goal is to help people take control of their daily health with trusted products, while expanding its global reach and investing in manufacturing capacity and brand development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Weybridge, United Kingdom

Founded

2022

Get referred to Haleon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 organic growth reached 2.6%; Q2 improved to 3.1% with North America rebound.
  • Emerging markets grew 6.3% in Q2 2026, led by China, India, and Latin America.
  • Haleon priced a $2 billion bond on August 13, 2026, refinancing March 2027 notes.

What critics are saying

  • Haleon terminated Eroxon U.S. rights on June 29, 2026 after slower-than-expected sales.
  • July 30, 2026 litigation revived claims over Advil Sinus maximum-strength labeling.
  • June 4, 2026 Gas-X recall and sub-4% growth against a 4%-6% target threaten valuation.

What makes Haleon unique

  • Haleon owns category-leading brands like Sensodyne, Advil, Panadol, and Centrum across 170 markets.
  • Its June 29, 2026 Microsoft partnership embeds AI across operations, data, and productivity.
  • Oral health innovation keeps driving share gains; H1 2026 oral health grew 7.3%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Parental Leave

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Investegate
Aug 13th, 2026
Haleon prices $2B bond offering to repurchase 2027 notes

Haleon's US subsidiary, Haleon US Capital LLC, has launched and priced a $2 billion fixed-rate bond offering. The offering comprises three tranches: $600 million in notes maturing in 2029 with a 4.625% coupon, $600 million in notes maturing in 2031 with a 4.875% coupon, and $800 million in notes maturing in 2036 with a 5.375% coupon. The offering is scheduled to settle on 21 August 2026. Payment of principal and interest is fully guaranteed by Haleon plc. The company plans to use the net proceeds, together with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% fixed rate senior notes due March 2027 and for general corporate purposes. Barclays Capital, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho Securities acted as joint book-running managers.

CCentral
Aug 4th, 2026
Daniela Cavinatto appointed general manager of Canada division for Haleon Canada.

Daniela Cavinatto appointed general manager of Canada division for Haleon Canada. Daniela Cavinatto joins the consumer health company with more than 25 years of international leadership experience. Haleon Canada has appointed Daniela Cavinatto as its new general manager of the Canada division. Cavinatto joins the consumer health company with more than 25 years of international leadership experience. In her new position, she will lead Haleon's Canadian operations as the company works to strengthen its market leadership and expand its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum. Industry experience across global markets. Prior to joining Haleon, Cavinatto served as general manager, Canada for The LEGO Group. During her time there, she led business growth by redefining market strategy, strengthening customer partnerships, and optimizing commercial investments. Throughout her career, Cavinatto has held senior executive roles across North America, Latin America, and Europe. Her background spans general management, sales, marketing, customer development, eCommerce, retail operations, and supply chain. "Daniela is an accomplished business leader with a proven ability to unlock growth, navigate complexity and deliver results in dynamic markets," said Nathalie Gerschtein, the Haleon North America president. "Canada is an important growth market for Haleon, and Daniela brings the commercial acumen, global perspective and leadership experience needed to help us build on our momentum. I am delighted to welcome Daniela to our North American leadership team and look forward to working with her as we strengthen our trusted brand portfolio and advance our leadership in consumer health." Portfolio reach and growth strategy. Haleon's Canadian product lineup holds a strong presence across retail channels. According to the company, six in 10 Canadian households rely on at least one Haleon brand. As of last year, the 2025 Product of The Year lineup included Tums Chewy Bites with Gas Relief. Cavinatto noted that the reach of the company's product line made the role an exciting opportunity. "Throughout my career, I've been inspired by opportunities to transform businesses, accelerate growth and help teams achieve ambitious goals," Cavinatto said. "That's what makes this opportunity so compelling. Haleon's portfolio of brands is rooted in science and consumer understanding with six in 10 Canadian households relying on at least one of our iconic brands. To lead a business with this kind of reach and impact is a true privilege and an opportunity that deeply inspires me." She added that she looks forward to working with internal teams, retail customers, and commercial partners to support the company's continued growth and innovation across Canada.

Yahoo Finance
Aug 1st, 2026
Haleon H1 2026: Organic growth hits 3.1%, margins up 120bp as North America rebounds

Haleon reported H1 2026 results ending 30 July, showing improved organic sales growth of 3.1% in Q2, with volume and mix up 1.4%. North America delivered strong progress at 3.1% growth, driven by shelf resets, innovation, and e-commerce momentum. Operating margin improved 120 basis points at constant currency, supported by supply chain efficiency and gross margin expansion of 140 basis points. Emerging markets achieved 6.3% growth in Q2, with India and Latin America leading performance. EPS grew 12% in H1. However, respiratory health remained weak, reducing organic growth by 150 basis points. Europe proved challenging with only 0.4% growth, whilst Middle East markets including Dubai and Pakistan experienced significant declines. The company acknowledged performing below its 4–6% medium-term growth target, with particular gaps in Europe and the Middle East.

Sharecast
Jul 30th, 2026
Oral health drives first-half growth at Haleon.

Oral health drives first-half growth at Haleon. 368.40p. 11:52 30/07/26. Haleon reported first-half revenue of £5.60bn on Thursday, up 2.2% on a reported basis and 2.6% organically, with second-quarter organic growth improving to 3.1% as North America strengthened. 10,913.70. 5,926.86. 5,860.81. 24,761.16. 11:51 30/07/26. Adjusted operating profit rose 8.2% at constant currencies to £1.36bn and the adjusted operating margin increased to 24.3%, while adjusted diluted earnings per share rose 12% to 10.3p. Oral Health was the strongest category, with second-quarter growth of 6.2%, while emerging markets grew 6.3%. The consumer healthcare group reiterated its full-year guidance for organic revenue growth of 3% to 5% and high-single-digit adjusted operating profit growth at constant currencies. "We delivered a good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2 and a more balanced price and volume/mix," said chief executive Brian McNamara. Haleon also raised its interim dividend 9% to 2.4p and said it had completed £457m of its planned £500m share buyback for 2026. At 0947 BST, shares in Haleon were down 2.03% at 372p. Reporting by Josh White for Sharecast.com.

KamCity
Jul 29th, 2026
Maker of Panadol launches new dual-action Pain Relief Tablets.

Maker of Panadol launches new dual-action Pain Relief Tablets. 29th July 2026 Haleon, the maker of Panadol, is expanding into the dual-action pain relief market with the launch of Panacombo Dual Action Pain Relief 200mg/500mg Film-coated Tablets (ibuprofen & paracetamol). The formulation of two pain-relieving ingredients is designed to be stronger and faster than ibuprofen alone, delivering effective pain relief from multiple pain types, including migraine, headache, backache, dental pain, period pain, joint or muscular pain, and aches linked with cold and flu. Haleon noted that Ibuprofen acid alone only provides effective pain relief in 37-45% of cases, while combining ibuprofen with paracetamol increases effectiveness to 67-70%, highlighting the enhanced pain relief achievable through a combined approach. Expanding the trusted Panadol range, Panacombo Dual Action Tablets are formulated to give your shoppers dual relief in one tablet. Paracetamol helps to block pain signals, and ibuprofen helps stop pain at the source. Monica Michalopoulou, Marketing Director at Haleon, said: "For 70 years, Panadol have been experts in pain relief, trusted to assist consumers with pain when needed. The launch of Panacombo, our dual-action pain-relief solution, expands our range of trusted products, and will offer retailers a strong proposition to help boost sales, encouraging shoppers to trade up and benefit from our trusted brand credentials." Panacombo Dual Action Tablets are rolling out in grocery stores at an RRP of £3.50. The launch will be supported by a wide-reaching consumer media activation and campaign later in the year.